Buprenorphine in the Intensive Care Unit: Commentary on the Unanswered Questions

David J. Gagnon; Melody J. Glenn; Aurora A. Quaye; Brian L. Erstad

doi:10.1177/10600280241254528

Buprenorphine in the Intensive Care Unit: Commentary on the Unanswered Questions

David J. Gagnon, Melody J. Glenn, Aurora A. Quaye, Brian L. Erstad

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

The removal of the X-waiver in the Mainstreaming Addiction Treatment (MAT) Act of 2023 has substantial implications for buprenorphine prescribing as one of the options to treat opioid use disorder. The purpose of this commentary is to discuss the unanswered questions regarding buprenorphine in the intensive care unit (ICU) including how the passage of the MAT Act will affect ICU providers, which patients should receive buprenorphine, what is the most appropriate route of administration and dose of buprenorphine, what medications interact with buprenorphine, and how can transitions of care be optimized for these patients.

Original language	English (US)
Pages (from-to)	184-188
Number of pages	5
Journal	Annals of Pharmacotherapy
Volume	59
Issue number	2
DOIs	https://doi.org/10.1177/10600280241254528
State	Published - Feb 2025

Keywords

buprenorphine
critical care
opioid use disorder

ASJC Scopus subject areas

Pharmacology (medical)

Access to Document

10.1177/10600280241254528

Cite this

@article{4272ff2a7abf4ca7a7a4f709ae8fbd40,

title = "Buprenorphine in the Intensive Care Unit: Commentary on the Unanswered Questions",

abstract = "The removal of the X-waiver in the Mainstreaming Addiction Treatment (MAT) Act of 2023 has substantial implications for buprenorphine prescribing as one of the options to treat opioid use disorder. The purpose of this commentary is to discuss the unanswered questions regarding buprenorphine in the intensive care unit (ICU) including how the passage of the MAT Act will affect ICU providers, which patients should receive buprenorphine, what is the most appropriate route of administration and dose of buprenorphine, what medications interact with buprenorphine, and how can transitions of care be optimized for these patients.",

keywords = "buprenorphine, critical care, opioid use disorder",

author = "Gagnon, {David J.} and Glenn, {Melody J.} and Quaye, {Aurora A.} and Erstad, {Brian L.}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2024.",

year = "2025",

month = feb,

doi = "10.1177/10600280241254528",

language = "English (US)",

volume = "59",

pages = "184--188",

journal = "Annals of Pharmacotherapy",

issn = "1060-0280",

publisher = "SAGE Publications Inc.",

number = "2",

}

TY - JOUR

T1 - Buprenorphine in the Intensive Care Unit

T2 - Commentary on the Unanswered Questions

AU - Gagnon, David J.

AU - Glenn, Melody J.

AU - Quaye, Aurora A.

AU - Erstad, Brian L.

N1 - Publisher Copyright: © The Author(s) 2024.

PY - 2025/2

Y1 - 2025/2

N2 - The removal of the X-waiver in the Mainstreaming Addiction Treatment (MAT) Act of 2023 has substantial implications for buprenorphine prescribing as one of the options to treat opioid use disorder. The purpose of this commentary is to discuss the unanswered questions regarding buprenorphine in the intensive care unit (ICU) including how the passage of the MAT Act will affect ICU providers, which patients should receive buprenorphine, what is the most appropriate route of administration and dose of buprenorphine, what medications interact with buprenorphine, and how can transitions of care be optimized for these patients.

AB - The removal of the X-waiver in the Mainstreaming Addiction Treatment (MAT) Act of 2023 has substantial implications for buprenorphine prescribing as one of the options to treat opioid use disorder. The purpose of this commentary is to discuss the unanswered questions regarding buprenorphine in the intensive care unit (ICU) including how the passage of the MAT Act will affect ICU providers, which patients should receive buprenorphine, what is the most appropriate route of administration and dose of buprenorphine, what medications interact with buprenorphine, and how can transitions of care be optimized for these patients.

KW - buprenorphine

KW - critical care

KW - opioid use disorder

UR - http://www.scopus.com/inward/record.url?scp=85193759731&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85193759731&partnerID=8YFLogxK

U2 - 10.1177/10600280241254528

DO - 10.1177/10600280241254528

M3 - Comment/debate

C2 - 38755998

AN - SCOPUS:85193759731

SN - 1060-0280

VL - 59

SP - 184

EP - 188

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

IS - 2

ER -

Buprenorphine in the Intensive Care Unit: Commentary on the Unanswered Questions

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this